In partnership with
But as you’re about to see, there’s a very good reason for us to do it.
Now, before we get into exactly what that is…
Let's talk about something that we haven’t talked about yet, and that’s the biomaterials sector.
Yes, biomaterials… because the sector’s been scorching hot. Over the last twelve months, some players in the space have delivered double-digit gains that’ve outpaced the broader market.
What’s the biomaterials market? Well, simply put, it’s the creation, production, and application of substances (natural and synthetic) that are engineered to interact with biological systems.
Biological systems like us, humans. Think implants, diagnostics, and regenerative therapies.
Global valuations? Up from $178 billion to projections over $488 billion by 2030- that's a 15.6% compound annual growth rate. Aging populations are begging for solutions to heal wounds, rebuild tissues, and skip brutal surgeries.
Most market news is noise. This free weekly newsletter cuts through the chaos to bring you a ~3-minute recap of what moved markets, why it matters, and what’s next. Clear insights you can actually use to invest smarter.
Add in 3D-printed scaffolds and hydrogels that act like the body's own repair kit, and you've got a market that's not just growing, it's exploding.
The winners are raking it in. Zimmer Biomet's up 25% on orthopedic implants with bio-coatings that slash recovery time.
Evonik Industries? Their biomaterials arm jumped 30% thanks to polymers streamlining drug delivery. Collagen Matrix is up 18%, cashing in on wound dressings that allow for healing twice as fast.
These aren't random pops taking advantage of a hot market. No, they're built on real demand for spinal fixes and ocular gels. Investors threw $400 million at the sector in Q1 alone, betting on firms turning sci-fi into reality.
Now, this new IPO, which I’ll share fully with IPO Stream Premium members, looks like it could end up being a very good investment.
See…
The company offers scaffolding tissue regeneration. Essentially, a product that uses a 3D porous structure to support the regrowth of damaged tissue. Sci-fi stuff.
Early trials? It looks like it is crushing it for cartilage and post-op seals, with a pipeline eyeing a multi-billion-dollar market.
Revenue's climbing, losses are shrinking, and the team's got vets from the big leagues. It's a high-reward bet with a price tag that may end up being a bargain. Of course, with every high reward bet we have risk.
Is the AI Bubble About to Burst? (95.2% Accurate Forecast)
NVIDIA officially reports earnings November 19, but you can get a sneak peek right now.
Not just for NVIDIA, but for dozens of public companies.
On Polymarket, the world's largest prediction market (with verified 95.2% accuracy), you can see what top forecasters believe will happen.
Our new Earnings Markets let you:
See real-time odds of NVIDIA beating estimates
Predict what executives will say on earnings calls
Profit directly from being right, regardless of stock price movement
Trade simple Yes/No outcomes instead of complex options
Will Jensen stun Wall Street again?
Or is the AI trade finally cooling off?
Top forecasters are already positioning.
Underwriting time. You know I prefer to ride with the heavy hitters, the big-name underwriters that can market the heck out of and fully support an IPO.
Yes, we've followed their trends, and they’ve paid off on many occasions. But here's the twist: for the first time, I'm ditching my rule of sticking with the giants, I’m doing something I never do, going with a smaller underwriter.
This new issue is with ThinkEquity, a boutique outfit that's sharp in mid-cap deals.
They don't have a flashy name like Goldman, but they've nailed the timing on some sleeper hits lately… smart allocations, big pull.
In this market, momentum's king, so I'm betting on trend-spotters over titans. It's calculated, not crazy.
This biomaterials wave? It's just picking up steam with FDA fast-tracks and global health shifts screaming opportunity.
I think this IPO's right in the sweet spot. Seemingly proven tech, huge potential and it’s in a market that’s going to be worth a half-trillion dollars in no time.
For the ticker and full breakdown, all you have to do is subscribe to IPO Stream premium. I truly hope you do, because this market’s been doing so well and this IPO could end up being a monster.
To subscribe to IPO Stream Premium (just $9 a month), visit HERE
